The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration

(2015) Karel G.M. Moons et al.   ANNALS OF INTERNAL MEDICINE

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation

(2014) Lars Wallentin et al.   CIRCULATION

Towards better clinical prediction models: seven steps for development and an ABCD for validation

(2014) E. W. Steyerberg et al.   EUROPEAN HEART JOURNAL

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy

(2014) Ziad Hijazi et al.   HEART

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

External validation of a Cox prognostic model: principles and methods

(2013) Patrick Royston et al.   BMC Medical Research Methodology

High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation

(2013) Ziad Hijazi et al.   CIRCULATION

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference

(2013) P. Kirchhof et al.   EUROPACE

Biomarkers in atrial fibrillation: a clinical review

(2013) Z. Hijazi et al.   EUROPEAN HEART JOURNAL

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

(2013) Ziad Hijazi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin

(2013) Ziad Hijazi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation

(2012) Ziad Hijazi et al.   CIRCULATION

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study

(2012) Leif Friberg et al.   EUROPEAN HEART JOURNAL

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

(2010) Harvey White et al.   AMERICAN HEART JOURNAL

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

(2010) Renato D. Lopes et al.   AMERICAN HEART JOURNAL

Moving the Tipping Point

(2010) Mark H. Eckman et al.  

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION